Background: Chronic kidney disease (CKD) exacerbates the risk of death due to cardiovascular disease (CVD). Modifications to blood lipid metabolism which manifest as increases in circulating triglycerides and reductions in high-density lipoprotein (HDL) cholesterol are thought to contribute to increased risk. In CKD patients, higher HDL cholesterol levels were not associated with reduced mortality risk. Recent research has revealed numerous mechanisms by which HDL could favourably influence CVD risk. In this study, we compared plasma levels of sphingosine-1-phosphate (S1P), HDL-associated S1P (HDL-S1P) and HDL-mediated protection against oxidative stress between CKD and control patients. Methods: High-density lipoprotein was individually is...
Decades of epidemiological studies have established the strong inverse relationship between high-den...
Cardiovascular disease (CVD) is the principal cause of mortality in chronic kidney disease (CKD) pat...
Background/Aims: Hypertriglyceridaemia (HTG) and reduction and dysfunction of high density lipoprote...
Background: Chronic kidney disease (CKD) exacerbates the risk of death due to cardiovascular disease...
Chronic kidney disease (CKD) exacerbates the risk of death due to cardiovascular disease (CVD). Modi...
Dyslipidemia is a major traditional risk factor for cardiovascular disease (CVD) in chronic kidney d...
In chronic kidney disease (CKD), the level of high-density lipoprotein (HDL) decreases markedly, but...
Aims: The vascular effects of high-density lipoproteins (HDL) differ under certain clinical conditio...
Objectives: Patients with chronic kidney disease (CKD) often present with reduced plasma HDL cholest...
ObjectivesThis study examined the functionality of high-density lipoprotein (HDL) in individuals wit...
Cardiovascular disease is the leading cause of death in end-stage renal disease (ESRD) patients trea...
In the general population, HDL cholesterol (HDL-C) is associated with reduced cardiovascular events....
End-stage renal disease (ESRD) is associated with a significant propensity for development of athero...
Several studies have shown that HDL has altered antioxidant and anti-inflammatory effects in chronic...
Chronic kidney disease (CKD) is associated with high cardiovascular risk. CKD patients exhibit a spe...
Decades of epidemiological studies have established the strong inverse relationship between high-den...
Cardiovascular disease (CVD) is the principal cause of mortality in chronic kidney disease (CKD) pat...
Background/Aims: Hypertriglyceridaemia (HTG) and reduction and dysfunction of high density lipoprote...
Background: Chronic kidney disease (CKD) exacerbates the risk of death due to cardiovascular disease...
Chronic kidney disease (CKD) exacerbates the risk of death due to cardiovascular disease (CVD). Modi...
Dyslipidemia is a major traditional risk factor for cardiovascular disease (CVD) in chronic kidney d...
In chronic kidney disease (CKD), the level of high-density lipoprotein (HDL) decreases markedly, but...
Aims: The vascular effects of high-density lipoproteins (HDL) differ under certain clinical conditio...
Objectives: Patients with chronic kidney disease (CKD) often present with reduced plasma HDL cholest...
ObjectivesThis study examined the functionality of high-density lipoprotein (HDL) in individuals wit...
Cardiovascular disease is the leading cause of death in end-stage renal disease (ESRD) patients trea...
In the general population, HDL cholesterol (HDL-C) is associated with reduced cardiovascular events....
End-stage renal disease (ESRD) is associated with a significant propensity for development of athero...
Several studies have shown that HDL has altered antioxidant and anti-inflammatory effects in chronic...
Chronic kidney disease (CKD) is associated with high cardiovascular risk. CKD patients exhibit a spe...
Decades of epidemiological studies have established the strong inverse relationship between high-den...
Cardiovascular disease (CVD) is the principal cause of mortality in chronic kidney disease (CKD) pat...
Background/Aims: Hypertriglyceridaemia (HTG) and reduction and dysfunction of high density lipoprote...